Usage Examples
- FDA accepted the NDA for filing, so the review clock is running.
- That gap is a refuse-to-file risk, not a review-issue risk.
- We are filing a 505(b)(2) NDA rather than a full 505(b)(1).
What is New Drug Application (NDA)?
A New Drug Application (NDA) is the marketing application a sponsor submits to obtain FDA approval to market a new drug in the United States, carrying the complete safety, effectiveness, manufacturing, and labeling record supporting that decision.
A New Drug Application exists because FDA does not approve a drug on the sponsor's conclusion, it approves on the underlying record. The NDA is the vehicle that carries that record into the agency's hands: every nonclinical study, every trial, every manufacturing control, and the proposed labeling, in a form a reviewer can independently evaluate and act on.
A New Drug Application covers seven technical sections plus the application form and a summary: chemistry, manufacturing and controls; nonclinical pharmacology and toxicology; human pharmacokinetics and bioavailability; microbiology; clinical data; statistics; and pediatric use. The NDA does not cover biological products, which are marketed under a BLA and a different statute, and it is not the generic route, which is the ANDA.
A New Drug Application is judged on completeness before it is judged on science. FDA determines within 60 days of receipt whether the NDA may be filed, and it may refuse to file for defects that have nothing to do with the data: an incomplete form, a missing translation, a submission in a format the agency cannot process. That first determination is operational, not scientific.
Not to be confused with
- ANDA
- the abbreviated route for a generic of a drug FDA already approved, leaning on the agency's prior finding for the reference product. An NDA has no prior finding to lean on and must carry its own complete safety and effectiveness record.
- BLA
- the marketing application for biological products, running under a different statute and a different review pathway. Same commercial objective as an NDA, different legal authority, so the content expectations and lifecycle rules do not transfer.
- IND
- the IND is what permits an unapproved drug to be shipped and studied in humans; the NDA is what permits it to be marketed. The IND opens the clinical program, the NDA closes it.
- NDA filing vs NDA approval
- filing is FDA's 60-day decision that the application is complete enough to review. It carries no signal about approval, and treating "filed" as a step toward approval misleads boards and investors.
An NDA is assessed first on whether it is complete and processable. These are the load-bearing obligations.
What you must do
- 1Submit a completed and signed application form containing the information FDA specifies21 CFR 314.50(a)
- 2Provide every technical section FDA requires, from chemistry, manufacturing and controls through pediatric use21 CFR 314.50(d)
- 3Deliver the submission in an electronic format FDA can process, review, and archive21 CFR 314.50(l)(5)
- 4Build the application to survive the filing determination FDA makes within 60 days of receipt21 CFR 314.101(a)(1)
- 5Clear every refuse-to-file ground before submitting, since those are completeness defects rather than scientific ones21 CFR 314.101(d)
Common mistakes
Treating the 60-day filing window as a formality
FDA may refuse to file an NDA, and when it does the substantive review never begins. The application sits while the sponsor rebuilds sections that were rejected on completeness, not on merit, and every downstream launch date moves with it.
Assembling the NDA at the end instead of throughout
the technical sections are built from work done years earlier across nonclinical, clinical, and CMC. Teams that defer assembly to the final months find gaps that can only be closed with new work, which is the most expensive possible moment to discover them.
Treating submission format as an IT problem
electronic submissions must be in a form FDA can process, review, and archive. A broken backbone, a bad hyperlink, or a failed validation is a regulatory defect that the agency catches, not a technical nuisance the publishing team can absorb quietly.
When This Matters
- FDA accepted the NDA for filing, so the review clock is running.
- That gap is a refuse-to-file risk, not a review-issue risk.
- We are filing a 505(b)(2) NDA rather than a full 505(b)(1).
Frequently Asked Questions
An NDA must contain a completed and signed application form, a summary detailed enough for a reader to gain a good general understanding of the data, and seven technical sections: chemistry, manufacturing and controls; nonclinical pharmacology and toxicology; human pharmacokinetics and bioavailability; microbiology; clinical data; statistics; and pediatric use. Each is defined in 21 CFR 314.50.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
